Mass cytometry
Mass Cytometry couples the single cell high-speed analysis associated with flow cytometry with the ability of atomic mass spectrometry to resolve up to a theoretical limit 100 different metal probes with minimal signal overlap. CyTOF technology currently allows the simultaneous quantification of up to fifty cell surface and intracellular antigens at the single cell level.
In contrast to flow cytometry, antibodies are labelled with stable transition element isotopes to stain cellular epitopes. There are three key advantages over fluorescence-based single cell platforms: 1) avoidance of autofluorescence signals from troublesome cells and tissues; 2) fast panel design capabilities as all antibodies are introduced at once; 3) ease of barcoding to multiplex samples in large scale acquisitions.
Equipment
We have a range of panels designed for human and murine cells ranging from lymphoid, myeloid and stromal cells, ready to adapt to your research needs.
Support
Conjugation of new antibodies is easy and panels can be personalised fast. Samples can be stained remotely and transported to our Facility after staining. The ease of panel design and personalisation makes the validation of single cell transcriptomics at the protein level fast, reliable and affordable. No lengthy optimisations of panels one fluorochrome at the time!
Coupled with powerful high dimensional analysis software, mass cytometry allows the comprehensive phenotyping of heterogeneous cell populations combined with functional profiling of signalling and cytokine pathways active within individual single cells derived from human and murine blood and tissues. We offer assistance with analysis performance and training. Tissue imaging will be also available in the near future.
Publications
-
Lymphocytic infiltration in multiple sclerosis.
Journal article
Mahla RS., (2024), Mult Scler Relat Disord, 85
-
Transmembrane domain-driven PD-1 dimers mediate T cell inhibition.
Journal article
Philips EA. et al, (2024), Sci Immunol, 9
-
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.
Journal article
Grandclément C. et al, (2024), Nat Commun, 15
-
The protocol of a clinical effectiveness trial comparing standard step up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomised controlled trial
Journal article
WATSON M. et al, (2024), Therapeutic Advances in Musculoskeletal Disease
Publications
-
Lymphocytic infiltration in multiple sclerosis.
Journal article
Mahla RS., (2024), Mult Scler Relat Disord, 85
-
Transmembrane domain-driven PD-1 dimers mediate T cell inhibition.
Journal article
Philips EA. et al, (2024), Sci Immunol, 9
-
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.
Journal article
Grandclément C. et al, (2024), Nat Commun, 15
-
The protocol of a clinical effectiveness trial comparing standard step up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomised controlled trial
Journal article
WATSON M. et al, (2024), Therapeutic Advances in Musculoskeletal Disease
Booking and access
Please contact Claudia Monaco or David Ahern.